Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291173 · ClinicalTrials.gov registry record · Phase 2
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 271
- Enrollment target
NCT01291173: Completed Phase 2 study, sponsored by Shire.
NCT01291173 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 271 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (104% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01291173, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 271 participants
- Enrollment target
Study Summary
To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
Primary Outcome
Binge day is defined as a day during which at least 1 binge episode occurs.
Interventions
- DRUG Placebo
- DRUG lisdexamfetamine dimesylate (SPD489)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2011-05-10 |
| Est. Completion | 2012-01-30 |
| Phase | Phase 2 |
What the finished NCT01291173 record still lists
NCT01291173 is an interventional study that assigns participants to a tested intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (104% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01291173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01291173 about?
NCT01291173 is a clinical study titled "Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder". To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week
What is the current status of trial NCT01291173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 271 participants. The study started on 2011-05-10. Estimated completion is 2012-01-30.
What interventions are being tested in trial NCT01291173?
The interventions under investigation include: Placebo (DRUG), lisdexamfetamine dimesylate (SPD489) (DRUG).
Who is sponsoring clinical trial NCT01291173?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01291173's enrollment target sits among peer trials
271 205th of 2000 higher than 1,796 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI